Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA Consortium

Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA Consortium

Abstract Vaccines based on mRNA technology have revolutionized the field. In fact, lipid nanoparticles (LNP) formulated with mRNA are the preferential vaccine platform used in the fight against SARS-CoV-2 infection, with wider application against other diseases. The high demand and property right pr...

Full description

Bibliographic Details
Main Authors: Laura Marcos-Villar, Beatriz Perdiguero, Shubaash Anthiya, Mireya L. Borrajo, Gustavo Lou, Lorenzo Franceschini, Ignasi Esteban, Pedro J. Sánchez-Cordón, Carmen Zamora, Carlos Óscar S. Sorzano, Luis Jordá, Laia Codó, Josep L. Gelpí, Marta Sisteré-Oró, Andreas Meyerhans, Kris Thielemans, Francisco Martínez-Jiménez, Núria López-Bigas, Felipe García, María J. Alonso, Montserrat Plana, Mariano Esteban, Carmen Elena Gómez
Format: Article
Language:English
Published: Nature Portfolio 2024-03-01
Series:npj Vaccines
Online Access:https://doi.org/10.1038/s41541-024-00838-8

Internet

https://doi.org/10.1038/s41541-024-00838-8

Similar Items